KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Amortization - Intangibles (2018 - 2025)

Emergent BioSolutions' Amortization - Intangibles history spans 8 years, with the latest figure at $16.3 million for Q4 2025.

  • For Q4 2025, Amortization - Intangibles changed 0.0% year-over-year to $16.3 million; the TTM value through Dec 2025 reached $65.1 million, changed 0.0%, while the annual FY2025 figure was $65.1 million, 0.0% changed from the prior year.
  • Amortization - Intangibles reached $16.3 million in Q4 2025 per EBS's latest filing, roughly flat from $16.3 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $17.9 million in Q4 2022 to a low of $14.0 million in Q4 2021.
  • Average Amortization - Intangibles over 5 years is $15.7 million, with a median of $16.2 million recorded in 2024.
  • Peak YoY movement for Amortization - Intangibles: rose 27.86% in 2022, then decreased 9.5% in 2023.
  • A 5-year view of Amortization - Intangibles shows it stood at $14.0 million in 2021, then increased by 27.86% to $17.9 million in 2022, then dropped by 9.5% to $16.2 million in 2023, then grew by 0.62% to $16.3 million in 2024, then rose by 0.0% to $16.3 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Amortization - Intangibles are $16.3 million (Q4 2025), $16.3 million (Q3 2025), and $16.2 million (Q2 2025).